Yahoo Finance Here Are the Top 10 Marijuana Stocks
This is what you’ve all been waiting for — here are the top 10 marijuana stocks on the TSX, ordered from smallest to largest.
Supreme Cannabis Company (TSXV:FIRE)
Mostly due to growing its share count by roughly 60% from a year ago, Supreme had about $80 million in cash as of March 31.
Supreme’s biggest news items for the summer months have been its supply agreements with the liquor boards of B.C., Alberta, and Manitoba.
Emerald Health Therapeutics (TSXV:EMH)
As of March 31, Emerald had cash and cash equivalents of just under $90 million. The company trades at around three times book and has impressive five-year average annual revenue growth per share of over 50%.
Emerald’s joint venture with Village Farms International, called Pure Sunfarms, now has a sales licence from Health Canada and aims for full-scale production at its 1.1-million-square-foot greenhouse by the end of 2018.
OrganiGram Holdings (TSXV:OGI)
As of May 31, OrganiGram had over $150 million in cash and short-term investments. Further, the company turned a profit this past quarter, with net income of a little less than $3 million.
Both Alberta and Manitoba have signed supply agreements with OrganiGram, and the company is working with Hiku Brands to supply Tokyo Smoke locations.
CannTrust Holdings (TSX:TRST)
CannTrust is profitable and trades at a price-to-earnings multiple of around 35 and a price-to-book ratio of about four.
The company’s partnership with Apotex, the largest generic pharmaceutical company in Canada, will give CannTrust global exposure and access to industry-leading R&D.
Hydropothecary (TSX:HEXO)
With cash and short-term investments of nearly $250 million as of April 30, Hydropothecary has loads of capital to work with. Like many others, the company’s financial position is supported by offerings of common shares, as it is yet to turn a profit.
Hydropothecary’s 42.5% interest in a joint venture with Molson Coors Canada aims to develop cannabis beverages for the future consumables market and presents another potential avenue for growth.
Green Organic Dutchman Holdings (TSX:TGOD)
As of March 31, TGOD was sitting on over $70 million in cash and cash equivalents, almost entirely fueled by share issuances; the company has nearly doubled its share count from a year ago.
The company has recently generated interest because it will perform a spinout transaction, likely in September, where it will distribute warrants to existing shareholders in a new corporation called TGOD Acquisitions.
Cronos Group (TSX:CRON)(NASDAQ:CRON)
Weakly profitable, but profitable nonetheless, Cronos trades at a price-to-earnings multiple of over 400 and a price-to-book ratio of roughly 6.5.
The recently formed five-year take-or-pay supply agreement between Cronos and Cura Select Canada will ensure that the company has a buyer for its crops going forward.
Aphria (TSX:APH)
Profitable and growing at an impressive clip, Aphria reported net income of nearly $30 million for the year ended May 31. Despite growing its share count by approximately 50% in the past year, the company still managed to more than quadruple EPS year over year.
Aphria trades at a price-to-earnings multiple of slightly more than 54 and a price-to-book ratio of roughly 1.8. Most recently, the company has signed an agreement to be the exclusive sales representative of We Grow.
Aurora Cannabis (TSX:ACB)
Aurora’s financing activities, including convertible notes and share issues, generated over $540 million in the nine months ended March 31.
With a market capitalization of nearly $6 billion, the company posted revenue of roughly $16 million and a net loss of almost $21 million for the quarter ended March 31.
Aurora is on track to spin out subsidiary Australis Capital, which will focus on U.S. acquisitions in both the cannabis space and real estate.
Canopy Growth (TSX:WEED)(NYSE:CGC)
With a market capitalization of over $9 billion, Canopy is the largest marijuana company on the TSX, and it is widely seen as the bellwether for the industry.
For this past quarter, the company reported revenue of almost $26 million and a loss of $0.39 per share.
Canopy’s latest deal with Constellation Brands, an investment of $5 billion, has sent shockwaves through the marijuana industry and has rekindled investor interest.
More reading
Free investor brief: Our 3 top SELL recommendations for 2018
This Is the Best Strategy to Rearrange Your TFSA for the Bear Market to Come
Fool contributor James Watkins-Strand has no position in any of the stocks mentioned.
